VarmX B.V. manufactures therapeutic proteins that rapidly restore hemostasis in patients experiencing acute bleeding. This technology provides a critical solution for medical emergencies by enabling immediate blood clotting, thereby reducing the risk of severe complications.
Funding
$86.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SBFounders
Product
Problem
Patients taking Factor Xa (FXa) inhibitors, a common class of anticoagulants, face a significant risk of life-threatening bleeding events due to trauma, surgery, or other medical emergencies. Current reversal agents have limitations, including incomplete or delayed hemostatic effects, potential for prothrombotic complications, and limited availability. This unmet need leaves a substantial portion of patients vulnerable to severe outcomes following major bleeding episodes.
Solution
VarmX develops novel recombinant proteins designed to rapidly and effectively reverse the anticoagulant effects of FXa inhibitors. Their lead candidate, VMX-C001, is a modified Factor Xa protein that directly binds and neutralizes FXa inhibitors, restoring normal blood clotting function. VMX-C001 offers a targeted approach to hemostasis by specifically addressing the mechanism of action of FXa inhibitors without introducing prothrombotic risks. This allows for immediate and complete reversal of anticoagulation, potentially improving patient outcomes and reducing the burden on healthcare systems.
Target Audience
The primary target audience includes hospitals, emergency rooms, and specialized care centers that treat patients on FXa inhibitors experiencing acute bleeding events, as well as hematologists and cardiologists managing anticoagulation therapy.
Features
- Recombinant modified Factor Xa protein with high affinity for FXa inhibitors
- Rapid and complete reversal of FXa inhibitor-induced anticoagulation
- Designed to avoid prothrombotic complications associated with other reversal agents
- Demonstrated efficacy in preclinical studies
- Potential for intravenous bolus administration for immediate effect